Global Cancer Biomarkers Market

1 INTRODUCTION OF GLOBAL CANCER BIOMARKERS MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CANCER BIOMARKERS MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION
5.1 Diagnostics
5.2 Research and Development
5.3 Prognostics
5.4 Risk Assessment
5.5 Other Applications

6 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE
6.1 Breast Cancer
6.2 Lung Cancer
6.3 Colorectal Cancer
6.4 Prostate Cancer
6.5 Non-Hodgkin’s Lymphoma
6.6 Melanoma
6.7 Leukemia
6.8 Thyroid Cancer
6.9 Bladder Cancer
6.10 Kidney Cancer
6.11 Other Cancer Types

7 GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
7.1 Omics Technologies
7.1.1 Proteomics
7.1.2 Genomics
7.1.3 Other Omics Technologies

7.2 Imaging Technologies
7.2.1 Ultrasound
7.2.2 Computed Tomography (Ct)
7.2.3 Magnetic Resonance Imaging (Mri)
7.2.4 Positron Emission Tomography (Pet)
7.2.5 Mammography

7.3 Immunoassays

7.4 Cytogenetics
7.4.1 in Situ Hybridization (Ish)
7.4.2 Other Cytogenetics-Based Tests
7.5 Bioinformatics

8 GLOBAL CANCER BIOMARKERS MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the World Regional Market Estimates and Forecasts, 2012 â€" 2025

9 GLOBAL CANCER BIOMARKERS MARKET COMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Thermo Fisher Scientific
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Bio-Rad Laboratories
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Roche Diagnostics
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Qiagen N.V.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Illumina
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 GE Healthcare
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Agilent Technologies
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Biomérieux SA
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Merck & Co.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Abbott Laboratories
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Becton, Dickinson and Company
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments
10.12 Danaher Corporation
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

10.13 Myriad Genetics
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Developments

10.14 Sysmex Corporation
10.14.1 Overview
10.14.2 Financial Performance
10.14.3 Product Outlook
10.14.4 Key Developments

10.15 Hologic
10.15.1 Overview
10.15.2 Financial Performance
10.15.3 Product Outlook
10.15.4 Key Developments

11 Appendix
11.1 Related Reports